Document Detail


Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver.
MedLine Citation:
PMID:  23143207     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Liver metastases in patients with cancer are associated with poor survival. We hypothesized that hepatic arterial infusion (HAI) of oxaliplatin combination therapy would have antitumor activity in these patients. PATIENTS AND METHODS: Patients with advanced cancer and predominant liver metastases were treated on a phase I study of HAI oxaliplatin in combination with systemic bevacizumab, with or without HAI or systemic fluorouracil and/or leucovorin and/or cetuximab. Patients were divided into two treatment arms according to KRAS mutational status and physician choice. A "3 + 3" design was used. RESULTS: Among 76 patients (median age 61 years; 34 women; median number of prior therapies 4), the most common cancer was colorectal (CRC) (n = 58). Overall, the only dose-limiting toxicity was Grade 3 diarrhea (n = 2). The most common treatment-related toxicities were hypertension (n = 40), nausea (n = 29), fatigue (n = 28), and transaminitis (n = 26). Of 76 patients, one (1 %) had a complete response (CR), 12 (16 %) had a partial response (PR), and 12 (16 %) had SD for ≥6 months (total CR/PR/SD ≥6 months 25/76 = 33 %). In CRC (n = 58), total CR/PR/SD ≥6 months was 31 % (n = 18). Both patients with pancreatic neuroendocrine tumors achieved a PR (24+ months) and a CR (6+ months). Time to treatment failure (TTF) on the current regimen was 3.5 versus 2.8 months on patients' prior systemic treatment (p = 0.37). CONCLUSIONS: HAI oxaliplatin combination therapy with 5-fluorouracil, leucovorin, bevacizumab, and/or cetuximab was well tolerated and had antitumor activity in selected heavily pretreated patients with predominant liver disease.
Authors:
Apostolia M Tsimberidou; Mark B Leick; Joann Lim; Siqing Fu; Jennifer Wheler; Sarina A Piha-Paul; David Hong; Gerald S Falchook; Aung Naing; Ishwaria M Subbiah; Adoneca Fortier; Rony Avritscher; Razelle Kurzrock
Related Documents :
20879797 - Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis ...
22988517 - The utility of scoring systems in predicting early and late mortality in alcoholic hepa...
23041587 - Sorafenib in patients with child-pugh class a and b advanced hepatocellular carcinoma: ...
11506957 - Compliance with follow-up and prognosis among patients with thin melanomas.
24841347 - Impact of extent of surgery on survival in patients with small nonfunctional pancreatic...
8342567 - Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-11
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  -     ISSN:  1432-0843     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA, atsimber@mdanderson.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Large aneurysm of left coronary sinus of Valsalva presenting with effort-related ventricular fibrill...
Next Document:  Synthesis and characterization of some new Schiff base complexes of group 13 elements, ab initio stu...